LaMattina: Fix pharma's reputation to end public mistrust

10/3/2013 | Forbes

The FDA has a system of checks and balances that takes into account that drugmakers pay for trials and report the results, and the way to reinforce public trust in clinical trials is to bolster the pharmaceutical industry's reputation, John LaMattina writes.

View Full Article in:

Forbes